Product
Casirivimab + Imdevimab
Aliases
casirivimab+imdevimab combination therapy, REGEN-COV™, REGN10933, REGN10933 + REGN10987, REGN10987 (2 other aliases)
4 clinical trials
1 indication
Indication
COVID-19Clinical trial
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19Status: Terminated, Estimated PCD: 2022-01-21
Clinical trial
The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2Status: Recruiting, Estimated PCD: 2024-06-14
Clinical trial
A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe DiseaseStatus: Terminated, Estimated PCD: 2022-06-30
Clinical trial
Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)Status: Completed, Estimated PCD: 2022-04-07